Alaunos Therapeutics (TCRT)
NASDAQ:TCRT
Want to see TCRT full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/ADate:―
No summary available
Positive Factors
Innovative Therapy Platform
Alaunos' proprietary TCR therapy platform harnesses the immune system to target cancer cells, offering a durable competitive advantage in oncology.
Negative Factors
Negative Cash Flow
Ongoing negative cash flow indicates operational cash outflows exceed inflows, necessitating external funding and impacting financial sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Therapy Platform
Alaunos' proprietary TCR therapy platform harnesses the immune system to target cancer cells, offering a durable competitive advantage in oncology.
Read all positive factors
Alaunos Therapeutics (TCRT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.09M
Dividend YieldN/A
Average Volume (3M)860.99K
Price to Earnings (P/E)―
Beta (1Y)-1.76
Revenue Growth-44.44%
EPS Growth23.15%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,378,253
10 Day Avg. Volume2,529,145
30 Day Avg. Volume860,987
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.92
Price to Sales (P/S)1258.64
P/FCF Ratio-2.12
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue940.66
Enterprise Value/Gross Profit-26.13
Enterprise Value/Ebitda-1.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Alaunos Therapeutics Business Overview & Revenue Model
Company Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and ...
How the Company Makes Money
Alaunos Therapeutics generates revenue primarily through the development and commercialization of its TCR-based therapies. The company may earn income through collaboration agreements, research and development partnerships, and potential licensing...
Alaunos Therapeutics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.00K | 10.00K | 5.00K | 2.92M | 398.00K |
| Gross Profit | 5.00K | 10.00K | -4.80M | 2.92M | 398.00K |
| EBITDA | -4.22M | -4.68M | -30.90M | -31.82M | -74.97M |
| Net Income | -4.18M | -4.68M | -35.14M | -37.73M | -78.75M |
Balance Sheet | |||||
| Total Assets | 2.97M | 2.75M | 8.26M | 64.94M | 94.86M |
| Cash, Cash Equivalents and Short-Term Investments | 1.39M | 1.09M | 6.06M | 39.06M | 76.05M |
| Total Debt | 0.00 | 0.00 | 0.00 | 20.07M | 30.09M |
| Total Liabilities | 813.00K | 692.00K | 1.96M | 26.38M | 36.81M |
| Stockholders Equity | 2.15M | 2.06M | 6.31M | 38.55M | 58.06M |
Cash Flow | |||||
| Free Cash Flow | -2.97M | -4.97M | -30.34M | -29.45M | -64.79M |
| Operating Cash Flow | -2.87M | -4.97M | -30.14M | -29.23M | -61.47M |
| Investing Cash Flow | -98.00K | 0.00 | 1.35M | -193.00K | -3.32M |
| Financing Cash Flow | 3.26M | 0.00 | -18.14M | 6.37M | 25.78M |
Alaunos Therapeutics Technical Analysis
Negative
2.92
Price Trends
3.00
Negative
3.16
Negative
3.01
Negative
Market Momentum
-0.06
Positive
46.55
Neutral
38.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRT, the sentiment is Negative. The current price of 2.92 is below the 20-day moving average (MA) of 2.96, below the 50-day MA of 3.00, and below the 200-day MA of 3.01, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 46.55 is Neutral, neither overbought nor oversold. The STOCH value of 38.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCRT.
Alaunos Therapeutics Risk Analysis
Alaunos Therapeutics disclosed 58 risk factors in its most recent earnings report. Alaunos Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alaunos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $6.09M | -1.51 | -167.97% | ― | -44.44% | 23.15% | |
43 Neutral | $4.27M | -0.13 | 212.59% | ― | -48.24% | 62.05% | |
| ― | $14.38M | -1.16 | -24.80% | ― | 3.70% | 3.82% | |
43 Neutral | $3.22M | -0.15 | -381.74% | ― | ― | 95.78% | |
41 Neutral | $2.27M | -0.52 | ― | ― | ― | 84.28% |
* Healthcare Sector Average
TCRT
Alaunos Therapeutics
2.55
0.31
13.84%
AIM
AIM ImmunoTech
0.52
-7.35
-93.42%
CYCN
Cyclerion Therapeutics
3.31
0.01
0.30%
GRI
GRI Bio
2.18
-52.42
-96.01%
CLDI
Calidi Biotherapeutics
0.24
-5.55
-95.91%
Alaunos Therapeutics Corporate Events
Business Operations and StrategyLegal Proceedings
Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer
Positive
Dec 23, 2025
On December 17, 2025, Alaunos Therapeutics, Inc. entered into a Settlement and Release Agreement with The University of Texas M.D. Anderson Cancer Center to resolve disputes over unpaid invoices tied to a 2019 research and development agreement. A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―